Evaluation of Analgesic Effect of Unani Pharmacopoeial Formulation Habb-E-Suranjan and Raughan-E-Suranjan in Wajaul Mafasil (Joints Pain) Patients: An Open Prospective Clinical Trial

Wajaul Mafasil (joint pain) is the most prevalent and common cause of morbidity and disability not only in India but also throughout the world. In spite of various scientific developments in conventional medicine, there is no specific therapy or cure available for joints pain particularly when the disease has progressed to chronic stage. Therefore, it is the need of the hour to explore new formulations from herbal sources which are safe and effective. The present trial was undertaken to scientifically validate the Unani pharmacopoeial compound formulations of Habb-e-Suranjan and Raughan-e-Suranjan for its safety and efficacy in patients with joints pain. Patients with joint pain, who gave written informed consent, were recruited in the study from general OPD of RRIUM, Chennai with the prior approval of the Institutional Ethics Committee. 97 patients completed the study treatment. The treatment protocol was followed for 14 days and the clinical evaluation was done on seventh and fourteenth day of the treatment. At the end of fourteenth day intensity of individual parameters like joints pain, swelling, tenderness and restriction of movement showed statistically significant improvement (p<0.05). Overall therapeutic response of the treatment observed in this study was 100%. It was observed that 47.4% cases were completely relieved; 51.4% cases were relieved while 1.2% cases showed partial relief after the treatment. The laboratory investigations showed that the drugs used in the study were safe as evident by its maintenance. It may be concluded that Habb-e-Suranjan in combination with Raughan-e-Suranjan possesses significant analgesic property and may be a better option for the patients of joint pain. Keywords: Arthritis, Joints pain, Wajaul Mafasil, Habb-e-Suranjan, Raughan-e-Suranjan